Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Restructuring Costs (2016)

Historic Restructuring Costs for Teva Pharmaceutical Industries (TEVJF) over the last 6 years, with Q4 2016 value amounting to $91.0 million.

  • Teva Pharmaceutical Industries' Restructuring Costs rose 4677.42% to $91.0 million in Q4 2016 from the same period last year, while for Dec 2016 it was $104.2 billion, marking a year-over-year increase of 7019.02%. This contributed to the annual value of $91.0 million for FY2016, which is 4677.42% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Restructuring Costs stood at $91.0 million for Q4 2016, which was up 4677.42% from $43.0 billion recorded in Q3 2016.
  • Teva Pharmaceutical Industries' 5-year Restructuring Costs high stood at $61.0 billion for Q3 2015, and its period low was $43.0 million during Q1 2013.
  • In the last 4 years, Teva Pharmaceutical Industries' Restructuring Costs had a median value of $85.5 million in 2014 and averaged $13.1 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Restructuring Costs tumbled by 3984.96% in 2014, and later soared by 4677.42% in 2016.
  • Quarter analysis of 4 years shows Teva Pharmaceutical Industries' Restructuring Costs stood at $133.0 million in 2013, then crashed by 39.85% to $80.0 million in 2014, then fell by 22.5% to $62.0 million in 2015, then surged by 46.77% to $91.0 million in 2016.
  • Its Restructuring Costs stands at $91.0 million for Q4 2016, versus $43.0 billion for Q3 2016 and $62.0 million for Q4 2015.